Skip to content
10-K

Annual Report

LB Pharmaceuticals Inc LBRX

0001193125-26-126368

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 23, 2026 28.67M sh
Stock Issued FY 2025 · Dec 31, 2025 464 sh
Stock Issued FY 2025 · Dec 31, 2024 253 sh
Shares Diluted FY 2025 · Dec 31, 2025 8.05M sh
Shares Diluted FY 2025 · Dec 31, 2024 358.23K sh
Capex FY 2025 · Dec 31, 2025 $52K
Capex FY 2025 · Dec 31, 2024 $769K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$35.21M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$53.05M
Cash And Equivalents FY 2025 · Dec 31, 2025 $250.17M
Cash And Equivalents FY 2025 · Dec 31, 2024 $22.98M
Stockholders Equity FY 2025 · Dec 31, 2025 $301.31M
Stockholders Equity FY 2025 · Dec 31, 2024 −$94.55M
Stockholders Equity FY 2025 · Dec 31, 2023 −$34.47M
Current Liabilities FY 2025 · Dec 31, 2025 $7.44M
Current Liabilities FY 2025 · Dec 31, 2024 $8.11M
Total Liabilities FY 2025 · Dec 31, 2025 $11.62M
Total Liabilities FY 2025 · Dec 31, 2024 $13.83M
Current Assets FY 2025 · Dec 31, 2025 $308.43M
Current Assets FY 2025 · Dec 31, 2024 $28.88M
Total Assets FY 2025 · Dec 31, 2025 $312.93M
Total Assets FY 2025 · Dec 31, 2024 $33.53M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.13
Eps Diluted FY 2025 · Dec 31, 2024 −$176.15
Eps Basic FY 2025 · Dec 31, 2025 −$3.13
Eps Basic FY 2025 · Dec 31, 2024 −$176.15
Sga Expense FY 2025 · Dec 31, 2025 $13.66M
Sga Expense FY 2025 · Dec 31, 2024 $13.66M
Rd Expense FY 2025 · Dec 31, 2025 $16.74M
Rd Expense FY 2025 · Dec 31, 2024 $51.17M
Net Income FY 2025 · Dec 31, 2025 −$25.21M
Net Income FY 2025 · Dec 31, 2024 −$63.1M